Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists

スポンサーリンク

概要

• 論文の詳細を見る
• 2009-04-10

著者

• Dewan Md.

  Aids Research Center National Institute Of Infectious Diseases

• YAMAMOTO Naoki

  AIDS Research Center, National Institute of Infectious Diseases

• Akari Hirofumi

  Laboratory Of Disease Control Tsukuba Primate Research Center National Institute Of Biomedical Innov

• Yamamoto Naoki

  Aids Research Center National Institute Of Infectious Diseases

• Iwasaki Yuki

  Laboratory Of Disease Control Tsukuba Primate Research Center National Institute Of Biomedical Innov

• MURAKAMI Tsutomu

  AIDS Research Center, National Institute of Infectious Diseases

• KUMAKURA Sei

  Biomedical Research Laboratories, Kureha Corporation

• YANAKA Mikiro

  Biomedical Research Laboratories, Kureha Corporation

• Murakami Tsutomu

  Aids Research Center National Institute Of Infectious Diseases

• Kumakura Sei

  Biomedical Research Laboratories Kureha Corporation

• Yanaka Mikiro

  Biomedical Research Laboratories Kureha Corporation

関連論文

• Synthesis of a CC Chemokine, vMIP-II, Encoded by Kaposi's Sarcoma-Associated Herpesvirus and Its Biological Activity
• Development of the Chemokine Receptor CXCR4 Antagonists as Multi-Pharmaceutical Agents Involving a New Class of Low Molecular Weight Antagonists
• Synthesis and Biological Evaluation of Peptidomimetic Analogs of the CXCR4 Antagonist FC131
• The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases Including AIDS, Cancer and Rheumatoid Arthritis
• New Leads of Low Molecular Weight CXCR4 Antagonists Based on Enhancement of the T140-based Pharmacophores
• CXCR4 Antagonists Identified as Anti-Cancer-Metastatic Agents
• HIV-cell Fusion Inhibitors Targeted to the HIV Second Receptor : T22 and Its Downsized Analogs with High Activity
• Design, Synthesis and Activity of Shortened Analogs of an Anti-HIV Peptide, T22
• Synthesis of Sulfated Deoxy-Ribofuranans Having Selective Anti-AIDS Virus Activity by Ring-Opening Copolymerization of 1,4-Anhydro Ribose Derivatives
• Molecular Size of an Anti-HIV Peptide, T22, Can Be Reduced without Loss of the Activity
• STRUCTURE-ACTIVITY RELATIONSHIPS OF TACHYPLESIN ANALOGS AS ANTI-HIV AGENT
• STRUCTURES AND ACTIVITIES OF TANNINS IN CRUDE DRUGS (4) : EFFECTS ON PHAGOCYTES AND VIRUSES
• Identification of Sequential Motifs Relevant to Inhibitory Activity against HIV Integrase
• Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists
• Ligand-independent higher-order multimerization of CXCR4, a G-protein-coupled chemokine receptor involved in targeted metastasis
• Separate elements are required for ligand-dependent and -independent internalization of metastatic potentiator CXCR4
• Efficient Synthesis of Cyclic RGD Pseudopeptide with (E)-Alkene Dipeptide Isostere and Its Biological Activity
• Identification of a Polyphemusin Analog(T22)-Zn(II) Complex by Mass Spectrometric Analysis and Its Anti-HIV Activity
• Identification of Binding Proteins of an Anti-HIV Peptide, T22
• Non-human primate surrogate model of hepatitis C virus infection
• Recombinant Vaccinia DIs Expressing Simian Immunodeficiency Virus Gag and Pol in Mammalian Cells Induces Efficient Cellular Immunity as a Safe Immunodeficiency Virus Vaccine Candidate
• The Normalization of Guinea Pig Leukocyte Fractions and Lymphocyte Subsets in Blood and Lymphoid Tissues using a Flow Cytometric Procedure
• Solution RNA Structures of the HIV-1 Dimerization Initiation Site in the Kissing-Loop and Extended-Duplex Dimers
• Development of Inhibitory Peptides against HIV-1 Integrase
• Structure-Activity Relationship Study of CXCR4 Antagonists on the Cyclic Pentapeptide Scaffold : Identification of New Pharmacophore Moieties
• Development of Fluorescent Labeled CXCR4 Specific Ligand for Imaging and Fluorescence-Based Screening
• Synthesis and Evaluation of CXCR4-derived Peptides Targeting the Development of AIDS Vaccines
• Structural Modulation Study of Inhibitory Compounds for Ribonuclease H Activity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase
• Double Oral Administration of Emtricitabine/Tenofovir Prior to Virus Exposure Protects against Highly Pathogenic Simian/Human Immunodeficiency Virus Infection in Macaques

もっと見る 閉じる

スポンサーリンク